Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Allison Andreas

Nurse Practitioner, Family La Crosse, WI Nurse Practitioner

NPI 1972007250 CMS profile 10517680

1836 South Ave, La Crosse, WI 54601

Open in the dashboard

General payments

$4,785

197 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Andreas of La Crosse, WI is reported in the CMS Open Payments database as having received $4,785 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,269 57
2024 General $732 29
2023 General $834 21
2022 General $1,252 63
2021 General $697 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Andreas
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Allison Andreas were reported at $1,269. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Allison Andreas Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $697 $124 $35–$379 $132
2022 $1,252 $141 $44–$430 $149
2023 $834 $154 $49–$476 $160
2024 $732 $165 $51–$504 $164
2025 $1,269 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $702 45 payments
  2. Atricure, Inc. $539 6 payments
  3. Novo Nordisk Inc $525 14 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $338 13 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $296 12 payments
  6. Janssen Pharmaceuticals, Inc $263 16 payments
  7. Abbott Laboratories $227 7 payments
  8. E.R. Squibb & Sons, L.L.C. $187 12 payments
  9. Novartis Pharmaceuticals Corporation $174 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $169 9 payments
  11. Other $1,365 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,419 194 payments
  2. Travel and Lodging $346 2 payments
  3. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $539 6 payments
  2. Ozempic $525 14 payments
  3. Repatha Cardiology $398 27 payments
  4. ATRICLIP LAA EXCLUSION SYSTEM $372 5 payments
  5. LifeVest $338 13 payments
  6. Kerendia $296 12 payments
  7. XARELTO $263 16 payments
  8. REPATHA Cardiovascular $253 17 payments
  9. VERQUVO $186 10 payments
  10. LEQVIO $174 7 payments
  11. Other $2,311 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

879

Median for Nurse Practitioner: 389

Drug cost

$125,700

Median for Nurse Practitioner: $21,885

Branded share of claims

23.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 70 $60,934
Entresto Sacubitril/Valsartan Brand 59 $41,786
Farxiga Dapagliflozin Propanediol Brand 16 $12,994
Metoprolol Succinate Generic 123 $1,984
Atorvastatin Calcium Generic 71 $834
Bumetanide Generic 17 $788
Furosemide Generic 112 $720
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 22 $680
Rosuvastatin Calcium Generic 49 $537
Amiodarone Hcl Generic 13 $513

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$9,585

Medicare's payments for the services billed

Medicare patients

120

Average age 78

Services billed

160

56 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Heart failure 57%
Atrial fibrillation 52%
Chronic kidney disease 47%
Arthritis 43%
Diabetes 30%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $117
$117 — —
Ozempic
  • Novo Nordisk Inc $117
$117 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $59
$59 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $50
$50 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record